New attack plan for rare leukemia: CAR-T cells + stem cell transplant
NCT ID NCT05870917
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests a new treatment for a rare and aggressive blood cancer called primary plasma cell leukemia. The approach combines chemotherapy, a stem cell transplant, and two infusions of specially engineered immune cells (CAR-T cells) that target the cancer. The goal is to see if this powerful combination can safely control the disease and improve survival in 20 newly diagnosed patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-BCMA CAR-T cells (a type of immune cell therapy) combined with chemotherapy (bortezomib, lenalidomide, dexamethasone) and a stem cell transplant
What this could lead to
If successful, this approach could offer a powerful way to control or even eliminate plasma cell leukemia in newly diagnosed patients, potentially leading to longer remission.
What could go wrong
This is a very small, early-phase study with only 20 participants, so results may not apply to everyone. The treatment involves strong chemotherapy and cell therapy, which can cause serious side effects like infections or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China